Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml
Z Gastroenterol 2007; 45(6): 525-574
DOI: 10.1055/s-2007-963232
DOI: 10.1055/s-2007-963232
Leitlinie
© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York
Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-(HBV-)Infektion: „Upgrade” der Leitlinie, AWMF-Register-Nr.: 021/011
Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011Further Information
Publication History
Manuskript eingetroffen: 27.4.2007
Manuskript akzeptiert: 9.5.2007
Publication Date:
06 June 2007 (online)

Koordination: U. Protzer, M. Dollinger, M. Cornberg
Konsensuskonferenz am 27.1.2007 (13.30 Uhr) in Göttingen
Literatur
- 1
Immunisation against hepatitis B.
Lancet.
1988;
1
875-876
MissingFormLabel
- 2
European Consensus Group on Hepatitis B Immunity .
Are booster immunisations needed for lifelong hepatitis B immunity?.
Lancet.
2000;
355
561-565
MissingFormLabel
- 3
Ahmed A, Keeffe E B.
Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
Am J Gastroenterol.
1999;
94
249-251
MissingFormLabel
- 4
Anandh U, Bastani B, Ballal S.
Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination
in maintenance hemodialysis patients.
Am J Nephrol.
2000;
20
53-56
MissingFormLabel
- 5
Anselmo D M, Ghobrial R M, Jung L C. et al .
New era of liver transplantation for hepatitis B: a 17-year single-center experience.
Ann Surg.
2002;
235
611-619
MissingFormLabel
- 6
Arribas J R, Gonzalez-Garcia J J, Lorenzo A. et al .
Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected
patients in Madrid, Spain.
AIDS.
2005;
19
1361-1365
MissingFormLabel
- 7
Arslan M, Wiesner R H, Sievers C. et al .
Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease.
Liver Transpl.
2001;
7
314-320
MissingFormLabel
- 8
Ascherio A, Zhang S M, Hernan M A. et al .
Hepatitis B vaccination and the risk of multiple sclerosis.
N Engl J Med.
2001;
344
327-332
MissingFormLabel
- 9
Averhoff F, Mahoney F, Coleman P. et al .
Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk
of hepatitis B virus infection.
Am J Prev Med.
1998;
15
1-8
MissingFormLabel
- 10
Awerkiew S, Daumer M, Reiser M. et al .
Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive,
anti-HBc negative lymphoma patient.
J Clin Virol.
2007;
38
83-86
MissingFormLabel
- 11
Ayoola E A, Johnson A O.
Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies
to infants.
Int J Gynaecol Obstet.
1987;
25
297-301
MissingFormLabel
- 12
Aziz A, Aziz S, Li D S. et al .
Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic
liver disease.
J Viral Hepat.
2006;
13
217-221
MissingFormLabel
- 13
Bae S H, Yoon S K, Choi J Y. et al .
Timing of lamivudine administration according to Child class in patients with decompensated
cirrhosis.
J Gastroenterol Hepatol.
2005;
20
1527-1532
MissingFormLabel
- 14
Banatvala J, Van Damme P, Oehen S.
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune
memory.
Vaccine.
2000;
19
877-885
MissingFormLabel
- 15
Bauer T, Jilg W.
Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost
protective antibodies after hepatitis B vaccination.
Vaccine.
2006;
24
572-577
MissingFormLabel
- 16
Benhamou Y.
Treatment algorithm for chronic hepatitis B in HIV-infected patients.
J Hepatol.
2006;
44
S90-S94
MissingFormLabel
- 17
Benhamou Y, Bochet M, Thibault V. et al .
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency
virus-infected patients.
Hepatology.
1999;
30
1302-1306
MissingFormLabel
- 18
Benhamou Y, Thibault V, Vig P. et al .
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant
hepatitis B and HIV-1.
J Hepatol.
2006;
44
62-67
MissingFormLabel
- 19
Benner K G, Lee R G, Keeffe E B. et al .
Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation.
Gastroenterology.
1992;
103
1307-1312
MissingFormLabel
- 20
Benvegnu L, Fattovich G, Noventa F. et al .
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma
in cirrhosis. A prospective study.
Cancer.
1994;
74
2442-2448
MissingFormLabel
- 21
Berger A, Doerr H W, Rabenau H F. et al .
High frequency of HCV infection in individuals with isolated antibody to hepatitis
B core antigen.
Intervirology.
2000;
43
71-76
MissingFormLabel
- 22
Bienzle U, Gunther M, Neuhaus R. et al .
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for
hepatitis B-related disease.
Hepatology.
2003;
38
811-819
MissingFormLabel
- 23
Bodsworth N, Donovan B, Nightingale B N.
The effect of concurrent human immunodeficiency virus infection on chronic hepatitis
B: a study of 150 homosexual men.
J Infect Dis.
1989;
160
577-582
MissingFormLabel
- 24
Bodsworth N J, Cooper D A, Donovan B.
The influence of human immunodeficiency virus type 1 infection on the development
of the hepatitis B virus carrier state.
J Infect Dis.
1991;
163
1138-1140
MissingFormLabel
- 25
Bortolotti F.
Treatment of chronic hepatitis B in children.
J Hepatol.
2003;
39 (Suppl 1)
S200-S205
MissingFormLabel
- 26
Bortolotti F, Guido M, Bartolacci S. et al .
Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year
longitudinal study.
Hepatology.
2006;
43
556-562
MissingFormLabel
- 27
Bortolotti F, Jara P, Barbera C. et al .
Long term effect of alpha interferon in children with chronic hepatitis B.
Gut.
2000;
46
715-718
MissingFormLabel
- 28
Brook G.
Prevention of viral hepatitis in HIV co-infection.
J Hepatol.
2006;
44
S104-S107
MissingFormLabel
- 29
Brook M G, Chan G, Yap I. et al .
Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with
chronic hepatitis B virus infection.
BMJ.
1989;
299
652-656
MissingFormLabel
- 30
Brook M G, McDonald J A, Karayiannis P. et al .
Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment
of chronic hepatitis B virus (HBV) infection: factors that influence response.
Gut.
1989;
30
1116-1122
MissingFormLabel
- 31
Bruguera M, Rodicio J L, Alcazar J M. et al .
Effects of different dose levels and vaccination schedules on immune response to a
recombinant DNA hepatitis B vaccine in haemodialysis patients.
Vaccine.
1990;
8 (Suppl)
S47-S49
MissingFormLabel
- 32
Brunetto M R, Oliveri F, Coco B. et al .
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated
patients: a long term cohort study.
J Hepatol.
2002;
36
263-270
MissingFormLabel
- 33
Buti M, Jardi R, Allende H. et al .
Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus
and human immunodeficiency virus infections?.
J Med Virol.
1996;
49
66-69
MissingFormLabel
- 34
Bzowej N, Chan H L, Lai C L. et al .
A randomized trial of telbivudine vs adefovir for HBeAg-positive chronic hepatitis
B.
Hepatology.
2006;
44
563A
MissingFormLabel
- 35
Cacciola I, Pollicino T, Squadrito G. et al .
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
N Engl J Med.
1999;
341
22-26
MissingFormLabel
- 36
Cardell K, Fryden A, Normann B.
Intradermal hepatitis B vaccination in health care workers. Response rate and experiences
from vaccination in clinical practise.
Scand J Infect Dis.
1999;
31
197-200
MissingFormLabel
- 37
Caredda F, Rossi E, d'Arminio M A. et al .
Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable
disease with different outcome.
J Infect Dis.
1985;
151
925-928
MissingFormLabel
- 38
Carlsson T, Struve J, Sonnerborg A. et al .
The anti-HBs response after 2 different accelerated intradermal and intramuscular
schemes for hepatitis B vaccination.
Scand J Infect Dis.
1999;
31
93-95
MissingFormLabel
- 39
Castells L, Vargas V, Rodriguez F. et al .
Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection
after liver transplantation.
Liver Transpl.
2002;
8
892-900
MissingFormLabel
- 40
Castelnau C, Le Gal F, Ripault M P. et al .
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative
RT-PCR for follow-up.
Hepatology.
2006;
44
728-735
MissingFormLabel
- 41
CDC .
Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis. Electronic Citation.
2004;
, www.cdc.gov/ncidod/diseases/hepatitis/b/hbv_ms.pdf
MissingFormLabel
- 42
Chalasani N, Smallwood G, Halcomb J. et al .
Is vaccination against hepatitis B infection indicated in patients waiting for or
after orthotopic liver transplantation?.
Liver Transpl Surg.
1998;
4
128-132
MissingFormLabel
- 43
Chan H L, Leung N W, Hui A Y. et al .
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing
pegylated interferon-alpha2b and lamivudine with lamivudine alone.
Ann Intern Med.
2005;
142
240-250
MissingFormLabel
- 44
Chan H L, Tang J L, Tam W. et al .
The efficacy of thymosin in the treatment of chronic hepatitis B virus infection:
a meta-analysis.
Aliment Pharmacol Ther.
2001;
15
1899-1905
MissingFormLabel
- 45
Chang T T, Gish R G, Man de R. et al .
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2006;
354
1001-1010
MissingFormLabel
- 46
Chang T T, Shiffman M, Tong M. et al .
Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic
hepatitis B (CHB).
Journal of Hepatology.
2004;
40
126
MissingFormLabel
- 47
Charest A F, McDougall J, Goldstein M B.
A randomized comparison of intradermal and intramuscular vaccination against hepatitis
B virus in incident chronic hemodialysis patients.
Am J Kidney Dis.
2000;
36
976-982
MissingFormLabel
- 48
Chen C J, Yang H I, Su J. et al .
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B
virus DNA level.
JAMA.
2006;
295
65-73
MissingFormLabel
- 49
Chen G, Lin W, Shen F. et al .
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver
disease in a prospective study.
Am J Gastroenterol.
2006;
101
1797-1803
MissingFormLabel
- 50
Chen J C, Chang M L, Lin J N. et al .
Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area.
World J Gastroenterol.
2005;
11
5289-5294
MissingFormLabel
- 51
Chen P M, Chiou T J, Fan F S. et al .
Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic
bone marrow transplantation.
Transplantation.
1999;
67
1425-1433
MissingFormLabel
- 52
Chen P M, Fan S, Liu C J. et al .
Changing of hepatitis B virus markers in patients with bone marrow transplantation.
Transplantation.
1990;
49
708-713
MissingFormLabel
- 53
Chen Y C, Sheen I S, Chu C M. et al .
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients
with or without concurrent infection.
Gastroenterology.
2002;
123
1084-1089
MissingFormLabel
- 54
Cheng A L.
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B
virus carriers with non-Hodgkin's lymphoma.
Blood.
1996;
87
1202
MissingFormLabel
- 55
Cheng A L, Hsiung C A, Su I J. et al .
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in
HBV-carriers with lymphoma.
Hepatology.
2003;
37
1320-1328
MissingFormLabel
- 56
Chien R N, Yeh C T, Tsai S L. et al .
Determinants for sustained HBeAg response to lamivudine therapy.
Hepatology.
2003;
38
1267-1273
MissingFormLabel
- 57
Christensen C, Bruden D, Livingston S. et al .
Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell
and Ishak liver biopsy scores in chronic hepatitis C patients.
J Viral Hepat.
2006;
13
652-658
MissingFormLabel
- 58
Chu C M, Liaw Y F.
Hepatitis B virus-related cirrhosis: natural history and treatment.
Semin Liver Dis.
2006;
26
142-152
MissingFormLabel
- 59
Chu C M, Yeh C T, Liaw Y F.
Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers
of hepatitis B virus.
Gut.
1999;
45
613-617
MissingFormLabel
- 60
Chuang W L, Dai C Y, Chang W Y. et al .
Viral interaction and responses in chronic hepatitis C and B coinfected patients with
interferon-alpha plus ribavirin combination therapy.
Antivir Ther.
2005;
10
125-133
MissingFormLabel
- 61
Clark F L, Drummond M W, Chambers S. et al .
Successful treatment with lamivudine for fulminant reactivated hepatitis B infection
following intensive therapy for high-grade non-Hodgkin's lymphoma.
Ann Oncol.
1998;
9
385-387
MissingFormLabel
- 62
Clemens R, Sanger R, Kruppenbacher J. et al .
Booster immunization of low- and non-responders after a standard three dose hepatitis
B vaccine schedule - results of a post-marketing surveillance.
Vaccine.
1997;
15
349-352
MissingFormLabel
- 63
Coates T, Wilson R, Patrick G. et al .
Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant
DNA vaccines.
Clin Ther.
2001;
23
392-403
MissingFormLabel
- 64
Cockcroft D W, Gault M H.
Prediction of creatinine clearance from serum creatinine.
Nephron.
1976;
16
31-41
MissingFormLabel
- 65
Cohard M, Poynard T, Mathurin P. et al .
Prednisone-interferon combination in the treatment of chronic hepatitis B: direct
and indirect metanalysis.
Hepatology.
1994;
20
1390-1398
MissingFormLabel
- 66
Colloredo G, Bellati G, Leandro G. et al .
Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new
„gray-zone” for the evaluation of „borderline” values.
J Hepatol.
1996;
25
644-648
MissingFormLabel
- 67
Colloredo M G, Bellati G, Leandro G. et al .
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations.
Arch Virol.
1993;
(Suppl 8)
203-211
MissingFormLabel
- 68
Colonno R J, Rose R, Baldick C J. et al .
Entecavir resistance is rare in nucleoside naive patients with hepatitis B.
Hepatology.
2006;
44
1656-1665
MissingFormLabel
- 69
Colonno R J, Rose R E, Pokornowski K. et al .
Assessment at three years shows high barrier to resistance is maintained in entecavir-treated
nucleoside naïve patients while resistance emergence increases over time in lamivudine
refractory patients.
Hepatology.
2006;
44
229A-230A
MissingFormLabel
- 70
Confavreux C, Suissa S, Saddier P. et al .
Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis
Study Group.
N Engl J Med.
2001;
344
319-326
MissingFormLabel
- 71
Cooksley W G.
Treatment with interferons (including pegylated interferons) in patients with hepatitis
B.
Semin Liver Dis.
2004;
24 (Suppl 1)
45-53
MissingFormLabel
- 72
Cooksley W G, Piratvisuth T, Lee S D. et al .
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive
chronic hepatitis B.
J Viral Hepat.
2003;
10
298-305
MissingFormLabel
- 73
Cortelezzi A, Vigano M, Zilioli V R. et al .
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell
chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
J Clin Virol.
2006;
35
467-469
MissingFormLabel
- 74
Cotonat T, Quiroga J A, Lopez-Alcorocho J M. et al .
Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment
of chronic hepatitis B e antibody-positive patients.
Hepatology.
2000;
31
502-506
MissingFormLabel
- 75
Craxi A, Di Bona D, Camma C.
Interferon-alpha for HBeAg-positive chronic hepatitis B.
J Hepatol.
2003;
39 (Suppl 1)
S99-S105
MissingFormLabel
- 76
Crespo J, Fabrega E, Casafont F. et al .
Severe clinical course of de novo hepatitis B infection after liver transplantation.
Liver Transpl Surg.
1999;
5
175-183
MissingFormLabel
- 77
Crespo J, Lozano J L, Echevarria S. et al .
Influence of hepatitis C virus infection and human immunodeficiency on the natural
history of chronic delta hepatitis.
Rev Esp Enferm Dig.
1994;
85
185-191
MissingFormLabel
- 78
D'Antiga L, Aw M, Atkins M. et al .
Combined lamivudine/interferon-alpha treatment in „immunotolerant” children perinatally
infected with hepatitis B: a pilot study.
J Pediatr.
2006;
148
228-233
MissingFormLabel
- 79
Dahmen A, Herzog-Hauff S, Bocher W O. et al .
Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or
without interleukin-2 in patients with chronic hepatitis B.
J Med Virol.
2002;
66
452-460
MissingFormLabel
- 80
Dai M S, Chao T Y.
Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy:
prophylactic or preemptive?.
Breast Cancer Res Treat.
2005;
92
95-96
MissingFormLabel
- 81
Dai M S, Wu P F, Lu J J. et al .
Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus
undergoing cytotoxic chemotherapy: a longitudinal study.
Support Care Cancer.
2004;
12
191-196
MissingFormLabel
- 82
Davies S E, Portmann B C, O'Grady J G. et al .
Hepatic histological findings after transplantation for chronic hepatitis B virus
infection, including a unique pattern of fibrosing cholestatic hepatitis.
Hepatology.
1991;
13
150-157
MissingFormLabel
- 83
De Feo T M, Poli F, Mozzi F. et al .
Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors:
a collaborative study.
Transplant Proc.
2005;
37
1238-1239
MissingFormLabel
- 84
De Maria N, Colantoni A, Friedlander L. et al .
The impact of previous HBV infection on the course of chronic hepatitis C.
Am J Gastroenterol.
2000;
95
3529-3536
MissingFormLabel
- 85
del Canho R, Grosheide P M, Mazel J A. et al .
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982 - 1992: protective
efficacy and long-term immunogenicity.
Vaccine.
1997;
15
1624-1630
MissingFormLabel
- 86
del C anho R, Grosheide P M, Voogd M. et al .
Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy
neonates: a comparison of three different vaccination schemes.
J Med Virol.
1993;
41
30-34
MissingFormLabel
- 87
Delaugerre C, Marcelin A G, Thibault V. et al .
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations
in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection
once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Antimicrob Agents Chemother.
2002;
46
1586-1588
MissingFormLabel
- 88
Dervite I, Hober D, Morel P.
Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who
was receiving rituximab.
N Engl J Med.
2001;
344
68-69
MissingFormLabel
- 89
Deutsch J, Wirth S.
Konsensus über die Behandlung der chronischen Hepatitis B im Kindesalter.
Monatsschr Kinderheilkd.
2002;
150
625-629
MissingFormLabel
- 90
Dhedin N, Douvin C, Kuentz M. et al .
Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation:
a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.
Transplantation.
1998;
66
616-619
MissingFormLabel
- 91
Di Bisceglie A, Lai C L, Gane E. et al .
Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year
efficacy in nucleoside-treated hepatitis B patients.
Hepatology.
2006;
44
230A-231A
MissingFormLabel
- 92
Di Marco V, Giacchino R, Timitilli A. et al .
Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre
study.
J Viral Hepat.
1996;
3
123-128
MissingFormLabel
- 93
Di Marco V, Marzano A, Lampertico P. et al .
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological
response to lamivudine.
Hepatology.
2004;
40
883-891
MissingFormLabel
- 94
Di Martino V, Lunel F, Cadranel J F. et al .
Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis
B.
J Viral Hepat.
1996;
3
253-260
MissingFormLabel
- 95
Di Martino V, Thevenot T, Boyer N. et al .
Serum alanine transaminase level is a good predictor of response to interferon alfa
therapy for chronic hepatitis B in human immunodeficiency virus-infected patients.
Hepatology.
2000;
31
1030-1031
MissingFormLabel
- 96
Di Martino V, Thevenot T, Colin J F. et al .
Influence of HIV infection on the response to interferon therapy and the long-term
outcome of chronic hepatitis B.
Gastroenterology.
2002;
123
1812-1822
MissingFormLabel
- 97
Dickson R C, Everhart J E, Lake J R. et al .
Transmission of hepatitis B by transplantation of livers from donors positive for
antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive
and Kidney Diseases Liver Transplantation Database.
Gastroenterology.
1997;
113
1668-1674
MissingFormLabel
- 98
Dienstag J L.
The role of liver biopsy in chronic hepatitis C.
Hepatology.
2002;
36
S152-S160
MissingFormLabel
- 99
Dienstag J L.
The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis
B.
J Hepatol.
2005;
42
158-162
MissingFormLabel
- 100
Dienstag J L, Cianciara J, Karayalcin S. et al .
Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Hepatology.
2003;
37
748-755
MissingFormLabel
- 101
Dienstag J L, Schiff E R, Wright T L. et al .
Lamivudine as initial treatment for chronic hepatitis B in the United States.
N Engl J Med.
1999;
341
1256-1263
MissingFormLabel
- 102
Dikici B, Bosnak M, Bosnak V. et al .
Combination therapy for children with chronic hepatitis B virus infection.
J Gastroenterol Hepatol.
2002;
17
1087-1091
MissingFormLabel
- 103
Dikici B, Ozgenc F, Kalayci A G. et al .
Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter
study.
J Gastroenterol Hepatol.
2004;
19
127-133
MissingFormLabel
- 104
Dore G J, Cooper D A, Barrett C. et al .
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B
virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating
Committee.
J Infect Dis.
1999;
180
607-613
MissingFormLabel
- 105
Douglas D D, Rakela J, Wright T L. et al .
The clinical course of transplantation-associated de novo hepatitis B infection in
the liver transplant recipient.
Liver Transpl Surg.
1997;
3
105-111
MissingFormLabel
- 106
Duclos P.
Safety of immunisation and adverse events following vaccination against hepatitis
B.
Expert Opin Drug Saf.
2003;
2
225-231
MissingFormLabel
- 107
Endo T, Sakai T, Fujimoto K. et al .
A possible role for lamivudine as prophylaxis against hepatitis B reactivation in
carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem
cell transplantation for non-Hodgkin's lymphoma.
Bone Marrow Transplant.
2001;
27
433-436
MissingFormLabel
- 108
Erhardt A, Blondin D, Hauck K. et al .
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is
more sensitive to interferon than genotype D.
Gut.
2005;
54
1009-1013
MissingFormLabel
- 109
Erhardt A, Gerlich W, Starke C. et al .
Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
Liver Int.
2006;
26
805-810
MissingFormLabel
- 110
Erhardt A, Sagir A, Guillevin L. et al .
Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination
of prednisolone, alpha-interferon and lamivudine.
J Hepatol.
2000;
33
677-683
MissingFormLabel
- 111
Evans T G, Schiff M, Graves B. et al .
The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic
hemodialysis patients who have failed primary vaccination.
Clin Nephrol.
2000;
54
138-142
MissingFormLabel
- 112
Fabrizi F, Martin P, Dixit V. et al .
HBsAg seropositive status and survival after renal transplantation: meta-analysis
of observational studies.
Am J Transplant.
2005;
5
2913-2921
MissingFormLabel
- 113
Fabrizio F, Bunnapradist S, Martin P.
Transplanting kidneys from donors with prior hepatitis B infection: one response to
the organ shortage.
J Nephrol.
2002;
15
605-613
MissingFormLabel
- 114
Farci P, Mandas A, Coiana A. et al .
Treatment of chronic hepatitis D with interferon alfa-2a.
N Engl J Med.
1994;
330
88-94
MissingFormLabel
- 115
Farci P, Roskams T, Chessa L. et al .
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of
advanced hepatic fibrosis.
Gastroenterology.
2004;
126
1740-1749
MissingFormLabel
- 116
Farci P, Smedile A, Lavarini C. et al .
Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating
acute hepatitis B progressive to chronicity.
Gastroenterology.
1983;
85
669-673
MissingFormLabel
- 117
Farrell G C.
Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities
for prevention and exploitation?.
J Gastroenterol Hepatol.
1999;
14
741-744
MissingFormLabel
- 118
Fattovich G, Boscaro S, Noventa F. et al .
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic
hepatitis type B.
J Infect Dis.
1987;
155
931-935
MissingFormLabel
- 119
Fattovich G, Brollo L, Boscaro S. et al .
Long-term effect of low dose recombinant interferon therapy in patients with chronic
hepatitis B.
J Hepatol.
1989;
9
331-337
MissingFormLabel
- 120
Fattovich G, Giustina G, Christensen E. et al .
Influence of hepatitis delta virus infection on morbidity and mortality in compensated
cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).
Gut.
2000;
46
420-426
MissingFormLabel
- 121
Firpi R J, Nelson D R.
Viral hepatitis: manifestations and management strategy.
Hematology Am Soc Hematol Educ Program.
2006;
375-380
MissingFormLabel
- 122
Flink H J, Zonneveld van M, Hansen B E. et al .
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg
loss is associated with HBV genotype.
Am J Gastroenterol.
2006;
101
297-303
MissingFormLabel
- 123
Floreani A, Boninsegna S, Lobello S. et al .
Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related
cirrhosis following lamivudine withdrawal.
Gastroenterol Clin Biol.
2006;
30
307-309
MissingFormLabel
- 124
Fontana R J, Hann H W, Perrillo R P. et al .
Determinants of early mortality in patients with decompensated chronic hepatitis B
treated with antiviral therapy.
Gastroenterology.
2002;
123
719-727
MissingFormLabel
- 125
Fontana R J, Keeffe E B, Carey W. et al .
Effect of lamivudine treatment on survival of 309 North American patients awaiting
liver transplantation for chronic hepatitis B.
Liver Transpl.
2002;
8
433-439
MissingFormLabel
- 126
Fornairon S, Pol S, Legendre C. et al .
The long-term virologic and pathologic impact of renal transplantation on chronic
hepatitis B virus infection.
Transplantation.
1996;
62
297-299
MissingFormLabel
- 127
Fouillard L, Serfaty L, Gozlan J.
Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced
intensity conditioning allogeneic stem cell transplantation.
Bone Marrow Transplant.
2006;
37
625-626
MissingFormLabel
- 128
Fukuda R, Ishimura N, Kushiyama Y. et al .
Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with
the amount of interferon-alpha receptor mRNA in the liver.
J Hepatol.
1997;
26
455-461
MissingFormLabel
- 129
Fung S K, Chae H B, Fontana R J. et al .
Virologic response and resistance to adefovir in patients with chronic hepatitis B.
J Hepatol.
2006;
44
283-290
MissingFormLabel
- 130
Fung S K, Wong F, Hussain M. et al .
Sustained response after a 2-year course of lamivudine treatment of hepatitis B e
antigen-negative chronic hepatitis B.
J Viral Hepat.
2004;
11
432-438
MissingFormLabel
- 131
Fytili P, Ciesek S, Manns M P. et al .
Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs
to anti-HBc negative recipients.
Transplantation.
2006;
81
808-809
MissingFormLabel
- 132
Gan S I, Devlin S M, Scott-Douglas N W. et al .
Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis
B infection.
Can J Gastroenterol.
2005;
19
625-629
MissingFormLabel
- 133
Gane E, Pilmore H.
Management of chronic viral hepatitis before and after renal transplantation.
Transplantation.
2002;
74
427-437
MissingFormLabel
- 134
Ganem D, Prince A M.
Hepatitis B virus infection - natural history and clinical consequences.
N Engl J Med.
2004;
350
1118-1129
MissingFormLabel
- 135
Garripoli A, Di Marco V, Cozzolongo R. et al .
Ribavirin treatment for chronic hepatitis D: a pilot study.
Liver.
1994;
14
154-157
MissingFormLabel
- 136
Gaudin J L, Trepo C.
Therapy of chronic delta hepatitis with alpha- and beta-interferon.
Prog Clin Biol Res.
1993;
382
345-352
MissingFormLabel
- 137
Geier M R, Geier D A.
Immunologic reactions and hepatitis B vaccine.
Ann Intern Med.
2001;
134
1155
MissingFormLabel
- 138 Gerlich W H, Thomssen R. Terminology, structure and laboratory diagnosis of hepatitis viruses. Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rhodes J Oxford Textbook of Clinical Hepatology Oxford; Oxford University press 1999: 828-869
MissingFormLabel
- 139
Ghany M G, Ayola B, Villamil F G. et al .
Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite
hepatitis B immune globulin prophylaxis.
Hepatology.
1998;
27
213-222
MissingFormLabel
- 140
Gigliotti A R, Fioredda F, Giacchino R.
Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation.
J Pediatr Hematol Oncol.
2003;
25
184-192
MissingFormLabel
- 141
Girard M.
Autoimmune hazards of hepatitis B vaccine.
Autoimmun Rev.
2005;
4
96-100
MissingFormLabel
- 142
Gish R G, Chang T T, Man R A. et al .
Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion
through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022).
Hepatology.
2005;
42
267A-268A
MissingFormLabel
- 143
Govindarajan de S, Chin K P, Redeker A G. et al .
Fulminant B viral hepatitis: role of delta agent.
Gastroenterology.
1984;
86
1417-1420
MissingFormLabel
- 144
Gregorio G V, Jara P, Hierro L. et al .
Lymphoblastoid interferon alfa with or without steroid pretreatment in children with
chronic hepatitis B: a multicenter controlled trial.
Hepatology.
1996;
23
700-707
MissingFormLabel
- 145
Grob P, Jilg W, Bornhak H. et al .
Serological pattern „anti-HBc alone”: report on a workshop.
J Med Virol.
2000;
62
450-455
MissingFormLabel
- 146
Gunsar F, Akarca U S, Ersoz G. et al .
Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.
Antivir Ther.
2005;
10
721-726
MissingFormLabel
- 147
Hadler S C, Alcala D M, Rivero D. et al .
Epidemiology and long-term consequences of hepatitis delta virus infection in the
Yucpa Indians of Venezuela.
Am J Epidemiol.
1992;
136
1507-1516
MissingFormLabel
- 148
Hadler S C, Monzon de M, Ponzetto A. et al .
Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela.
Ann Intern Med.
1984;
100
339-344
MissingFormLabel
- 149
Hadler S C, Francis D P, Maynard J E. et al .
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.
N Engl J Med.
1986;
315
209-214
MissingFormLabel
- 150
Hadler S C, Judson F N, O'Malley P M. et al .
Outcome of hepatitis B virus infection in homosexual men and its relation to prior
human immunodeficiency virus infection.
J Infect Dis.
1991;
163
454-459
MissingFormLabel
- 151
Hadziyannis S J, Papatheodoridis G V, Dimou E. et al .
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative
chronic hepatitis B.
Hepatology.
2000;
32
847-851
MissingFormLabel
- 152
Hadziyannis S J, Sevastianos V, Rapti I. et al .
Sustained biochemical and virological remission after discontinuation of 4 to 5 years
of adefovir dipivoxil treatment in HBeAg-negative chronic hepatitis B.
Hepatology.
2006;
44
231A
MissingFormLabel
- 153
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
N Engl J Med.
2005;
352
2673-2681
MissingFormLabel
- 154
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for
up to 5 Years.
Gastroenterology.
2006;
131
1743-1751
MissingFormLabel
- 155
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis
B.
N Engl J Med.
2003;
348
800-807
MissingFormLabel
- 156
Hartman C, Berkowitz D, Eshach-Adiv O. et al .
Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive
to interferon.
J Pediatr Gastroenterol Nutr.
2006;
43
494-498
MissingFormLabel
- 157
Hartwig M G, Patel V, Palmer S M. et al .
Hepatitis B core antibody positive donors as a safe and effective therapeutic option
to increase available organs for lung transplantation.
Transplantation.
2005;
80
320-325
MissingFormLabel
- 158
Hasselhorn H M, Kralj N, Hofmann F. et al .
Non- and low-response after preventive hepatitis B vaccination.
Gesundheitswesen.
1997;
59
321-328
MissingFormLabel
- 159
Heintges T, Petry W, Kaldewey M. et al .
Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha
nonresponders with chronic hepatitis B.
Dig Dis Sci.
2001;
46
901-906
MissingFormLabel
- 160
Henderson E A, Louie T J, Ramotar K. et al .
Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular
vaccination of healthcare workers.
Infect Control Hosp Epidemiol.
2000;
21
264-269
MissingFormLabel
- 161
Hernan M A, Jick S S, Olek M J. et al .
Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective
study.
Neurology.
2004;
63
838-842
MissingFormLabel
- 162
Hillis W D, Hillis A, Walker W G.
Hepatitis B surface antigenemia in renal transplant recipients. Increased mortality
risk.
JAMA.
1979;
242
329-332
MissingFormLabel
- 163
Hoff J, Bani-Sadr F, Gassin M. et al .
Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving
lamivudine as a component of anti-human immunodeficiency virus regimens.
Clin Infect Dis.
2001;
32
963-969
MissingFormLabel
- 164
Hom X, Little N R, Gardner S D. et al .
Predictors of virologic response to Lamivudine treatment in children with chronic
hepatitis B infection.
Pediatr Infect Dis J.
2004;
23
441-445
MissingFormLabel
- 165
Hoofnagle J H, Seeff L B.
Peginterferon and ribavirin for chronic hepatitis C.
N Engl J Med.
2006;
355
2444-2451
MissingFormLabel
- 166
Housset C, Pol S, Carnot F. et al .
Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis
B virus infections in 260 chronic carriers of hepatitis B virus.
Hepatology.
1992;
15
578-583
MissingFormLabel
- 167
Hsu Y S, Chien R N, Yeh C T. et al .
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic
hepatitis B.
Hepatology.
2002;
35
1522-1527
MissingFormLabel
- 168
Hui A Y, Chan H L, Cheung A Y. et al .
Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon.
Aliment Pharmacol Ther.
2005;
22
519-528
MissingFormLabel
- 169
Hui C K, Cheung W W, Au W Y. et al .
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with
haematological malignancy on completion of cytotoxic chemotherapy.
Gut.
2005;
54
1597-1603
MissingFormLabel
- 170
Hui C K, Cheung W W, Zhang H Y. et al .
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing
cytotoxic chemotherapy.
Gastroenterology.
2006;
131
59-68
MissingFormLabel
- 171
Hui C K, Lau E, Wu H. et al .
Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection.
J Clin Virol.
2006;
35
185-192
MissingFormLabel
- 172
Huo T I, Wu J C, Lai C R. et al .
Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular
carcinoma with or without hepatitis D virus superinfection.
J Hepatol.
1996;
25
439-444
MissingFormLabel
- 173
Iannitto E, Minardi V, Calvaruso G. et al .
Hepatitis B virus reactivation and alemtuzumab therapy.
Eur J Haematol.
2005;
74
254-258
MissingFormLabel
- 174
Idilman R, Arat M, Soydan E. et al .
Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation
in hepatitis B virus carriers with malignancies.
J Viral Hepat.
2004;
11
141-147
MissingFormLabel
- 175
Idilman R, Colantoni A, De Maria N. et al .
Impaired antibody response rates after high dose short interval hepatitis B virus
vaccination of immunosuppressed individuals.
Hepatogastroenterology.
2003;
50
217-221
MissingFormLabel
- 176
Ikeda K, Shiga Y, Takahashi A. et al .
Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during
imatinib mesylate treatment.
Leuk Lymphoma.
2006;
47
155-157
MissingFormLabel
- 177
Ilan Y, Ashur Y, Tur-Kaspa R. et al .
Chronic hepatitis C virus infection with exposure to hepatitis B virus.
Isr J Med Sci.
1994;
30
259-263
MissingFormLabel
- 178
Iloeje U H, Yang H I, Su J. et al .
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Gastroenterology.
2006;
130
678-686
MissingFormLabel
- 179
Imbert-Bismut F, Ratziu V, Pieroni L. et al .
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection:
a prospective study.
Lancet.
2001;
357
1069-1075
MissingFormLabel
- 180
Institute of Medicine - Report .
Hepatitis B vaccine and demyelinating neurological disorders. Electronic Citation.
2002;
, www.cdc.gov/nip/vaccine/hep/hepb/iom.htm
MissingFormLabel
- 181
Iwai K, Tashima M, Itoh M. et al .
Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative,
HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive
period.
Bone Marrow Transplant.
2000;
25
105-108
MissingFormLabel
- 182
Jang J W, Choi J Y, Bae S H. et al .
Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in
patients with hepatocellular carcinoma.
J Hepatol.
2004;
41
427-435
MissingFormLabel
- 183
Jang J W, Choi J Y, Bae S H. et al .
A randomized controlled study of preemptive lamivudine in patients receiving transarterial
chemo-lipiodolization.
Hepatology.
2006;
43
233-240
MissingFormLabel
- 184
Janssen H L, Zonneveld van M, Senturk H. et al .
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive
chronic hepatitis B: a randomised trial.
Lancet.
2005;
365
123-129
MissingFormLabel
- 185
Janssen H L, Zonneveld van M, Nunen A B. et al .
Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral
treatment and mutations in the hepatitis B virus genome.
Eur J Gastroenterol Hepatol.
2004;
16
801-807
MissingFormLabel
- 186
Jardi van R, Rodriguez F, Buti M. et al .
Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral
genotypes and hepatitis B precore and basal core promoter mutations on viral replicative
interference.
Hepatology.
2001;
34
404-410
MissingFormLabel
- 187
Jilg W, Hottentrager B, Weinberger K. et al .
Prevalence of markers of hepatitis B in the adult German population.
J Med Virol.
2001;
63
96-102
MissingFormLabel
- 188
Jilg W, Schmidt M, Deinhardt F.
Four-year experience with a recombinant hepatitis B vaccine.
Infection.
1989;
17
70-76
MissingFormLabel
- 189
Jilg W, Schmidt M, Deinhardt F.
Inoculation failure following hepatitis B vaccination. The effect of additional vaccinations.
Dtsch Med Wochenschr.
1990;
115
1545-1548
MissingFormLabel
- 190
Jonas M M, Mizerski J, Badia I B. et al .
Clinical trial of lamivudine in children with chronic hepatitis B.
N Engl J Med.
2002;
346
1706-1713
MissingFormLabel
- 191
Kanaan N, Horsmans Y, Goffin E.
Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection.
Clin Nephrol.
2006;
65
208-210
MissingFormLabel
- 192
Kanwal F, Farid M, Martin P. et al .
Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
Am J Gastroenterol.
2006;
101
2076-2089
MissingFormLabel
- 193
Kapoor D, Aggarwal S R, Singh N P. et al .
Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis
B virus vaccine in previously unvaccinated haemodialysis patients.
J Viral Hepat.
1999;
6
405-409
MissingFormLabel
- 194
Kapoor D, Guptan R C, Wakil S M. et al .
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.
J Hepatol.
2000;
33
308-312
MissingFormLabel
- 195
Kelly D.
Viral hepatitis in children.
Adv Exp Med Biol.
2004;
549
83-90
MissingFormLabel
- 196
Kempinska A, Kwak E J, Angel J B.
Reactivation of hepatitis B infection following allogeneic bone marrow transplantation
in a hepatitis B-immune patient: case report and review of the literature.
Clin Infect Dis.
2005;
41
1277-1182
MissingFormLabel
- 197
Kim K H, Ahn S H, Chung H Y. et al .
Hepatitis B virus infection after renal transplantation in the presence of antibody
to hepatitis B surface antigen immunity.
J Gastroenterol Hepatol.
2004;
19
847-853
MissingFormLabel
- 198
Knoll A, Boehm S, Hahn J. et al .
Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic
stem cell transplantation.
Bone Marrow Transplant.
2004;
33
925-929
MissingFormLabel
- 199
Knoll A, Hartmann A, Hamoshi H. et al .
Serological pattern „anti-HBc alone”: characterization of 552 individuals and clinical
significance.
World J Gastroenterol.
2006;
12
1255-1260
MissingFormLabel
- 200
Kohmoto M, Enomoto M, Tamori A. et al .
Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle
immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
J Med Virol.
2005;
75
235-239
MissingFormLabel
- 201
Kondili L A, Osman H, Mutimer D.
The use of lamivudine for patients with acute hepatitis B (a series of cases).
J Viral Hepat.
2004;
11
427-431
MissingFormLabel
- 202
Konopnicki D, Mocroft A, Wit de S. et al .
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral
therapy and increased mortality in the EuroSIDA cohort.
AIDS.
2005;
19
593-601
MissingFormLabel
- 203
Korenman J, Baker B, Waggoner J. et al .
Long-term remission of chronic hepatitis B after alpha-interferon therapy.
Ann Intern Med.
1991;
114
629-634
MissingFormLabel
- 204
Kruger M, Boker K H, Zeidler H. et al .
Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon
alfa-2b.
J Hepatol.
1997;
26
935-939
MissingFormLabel
- 205
Kumagai K, Takagi T, Nakamura S. et al .
Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological
study in Japan.
Ann Oncol.
1997;
8 (Suppl 1)
107-109
MissingFormLabel
- 206
Kumar M, Satapathy S, Monga R. et al .
A randomized controlled trial of lamivudine to treat acute hepatitis B.
Hepatology.
2007;
45
97-101
MissingFormLabel
- 207
Kuo A, Dienstag J L, Chung R T.
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis
B.
Clin Gastroenterol Hepatol.
2004;
2
266-272
MissingFormLabel
- 208
Lackner H, Moser A, Benesch M. et al .
Serological and molecular response on combined antiviral treatment in children with
chronic hepatitis B after pediatric malignancy.
J Clin Virol.
2002;
25 (Suppl 3)
S73-S79
MissingFormLabel
- 209
Lai C L, Chien R N, Leung N W. et al .
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine
Study Group.
N Engl J Med.
1998;
339
61-68
MissingFormLabel
- 210
Lai C L, Dienstag J, Schiff E. et al .
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for
patients with chronic hepatitis B.
Clin Infect Dis.
2003;
36
687-696
MissingFormLabel
- 211
Lai C L, Gane E, Hsu C W. et al .
Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical
and antiviral efficacy for telbivudine vs lamivudine.
Hepatology.
2006;
44
222A
MissingFormLabel
- 212
Lai C L, Gane E, Liaw Y F. et al .
Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: First-year results from
the international phase III globe trial.
Hepatology.
2005;
42
748A
MissingFormLabel
- 213
Lai C L, Leung N, Teo E K. et al .
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis
B e antigen-positive chronic hepatitis B.
Gastroenterology.
2005;
129
528-536
MissingFormLabel
- 214
Lai C L, Shouval D, Lok A S. et al .
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2006;
354
1011-1020
MissingFormLabel
- 215
Lampertico P, Del Ninno E, Vigano M. et al .
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month
interferon therapy.
Hepatology.
2003;
37
756-763
MissingFormLabel
- 216
Lampertico P, Marzano A, Levrero M. et al .
Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for
lamivudine-resistant patients with HBeAg-negative chronic hepatitis B.
Hepatology.
2006;
44
693A-694A
MissingFormLabel
- 217
Lampertico P, Vigano M, Manenti E. et al .
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic
resistance to lamivudine.
Hepatology.
2005;
42
1414-1419
MissingFormLabel
- 218
Lang M, Neumann U, Kahl A. et al .
Long-term outcome of 27 patients after combined liver-kidney transplantation.
Transplant Proc.
2001;
33
1440-1441
MissingFormLabel
- 219
Lau D T, Doo E, Park Y. et al .
Lamivudine for chronic delta hepatitis.
Hepatology.
1999;
30
546-549
MissingFormLabel
- 220
Lau D T, Everhart J, Kleiner D E. et al .
Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.
Gastroenterology.
1997;
113
1660-1667
MissingFormLabel
- 221
Lau D T, Kleiner D E, Park Y. et al .
Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy.
Gastroenterology.
1999;
117
1229-1233
MissingFormLabel
- 222
Lau G K, He M L, Fong D Y. et al .
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic
cell transplantation.
Hepatology.
2002;
36
702-709
MissingFormLabel
- 223
Lau G K, Liang R, Chiu E K. et al .
Hepatic events after bone marrow transplantation in patients with hepatitis B infection:
a case controlled study.
Bone Marrow Transplant.
1997;
19
795-799
MissingFormLabel
- 224
Lau G K, Lok A S, Liang R H. et al .
Clearance of hepatitis B surface antigen after bone marrow transplantation: role of
adoptive immunity transfer.
Hepatology.
1997;
25
1497-1501
MissingFormLabel
- 225
Lau G K, Piratvisuth T, Luo K X. et al .
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic
hepatitis B.
N Engl J Med.
2005;
352
2682-2695
MissingFormLabel
- 226
Lau G K, Suri D, Liang R. et al .
Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive
transfer of immunity to hepatitis B core antigen.
Gastroenterology.
2002;
122
614-624
MissingFormLabel
- 227
Lau G K, Yiu H H, Fong D Y. et al .
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients
undergoing chemotherapy.
Gastroenterology.
2003;
125
1742-1749
MissingFormLabel
- 228
Lau J Y, Smith H M, Chaggar K. et al .
Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection.
J Med Virol.
1991;
33
273-276
MissingFormLabel
- 229
Laubscher B, Gehri M, Roulet M. et al .
Survival of infantile fulminant hepatitis B and treatment with Lamivudine.
J Pediatr Gastroenterol Nutr.
2005;
40
518-520
MissingFormLabel
- 230
Lavanchy D.
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging
prevention and control measures.
J Viral Hepat.
2004;
11
97-107
MissingFormLabel
- 231
Law J K, Ho J K, Hoskins P J. et al .
Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B
surface antigen-negative, hepatitis B core antibody-positive patient: potential implications
for future prophylaxis recommendations.
Leuk Lymphoma.
2005;
46
1085-1089
MissingFormLabel
- 232
Le Gal F, Gordien E, Affolabi D. et al .
Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates
different patterns of virological response to interferon therapy in chronically infected
patients.
J Clin Microbiol.
2005;
43
2363-2369
MissingFormLabel
- 233
Leaw S J, Yen C J, Huang W T. et al .
Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients
with aggressive lymphoma receiving chemotherapy.
Ann Hematol.
2004;
83
270-275
MissingFormLabel
- 234
Lee C, Gong Y, Brok J. et al .
Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis
B surface antigen: systematic review and meta-analysis.
BMJ.
2006;
332
328-336
MissingFormLabel
- 235
Lee C, Gong Y, Brok J. et al .
Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive
mothers.
Cochrane Database Syst Rev CD004790.
2006;
MissingFormLabel
- 236
Lee G W, Ryu M H, Lee J L. et al .
The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B
surface antigen (HBs Ag)-positive patients with Non-Hodgkin’s lymphoma who receive
cytotoxic chemotherapy.
J Korean Med Sci.
2003;
18
849-854
MissingFormLabel
- 237
Lee K M, Cho S W, Kim S W. et al .
Effect of virological response on post-treatment durability of lamivudine-induced
HBeAg seroconversion.
J Viral Hepat.
2002;
9
208-212
MissingFormLabel
- 238
Lee W C, Wu M J, Cheng C H. et al .
Lamivudine is effective for the treatment of reactivation of hepatitis B virus and
fulminant hepatic failure in renal transplant recipients.
Am J Kidney Dis.
2001;
38
1074-1081
MissingFormLabel
- 239
Lee Y S, Suh D J, Lim Y S. et al .
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic
hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Hepatology.
2006;
43
1385-1391
MissingFormLabel
- 240
Li Y H, He Y F, Jiang W Q. et al .
Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis
B virus carriers who receive chemotherapy for lymphoma.
Cancer.
2006;
106
1320-1325
MissingFormLabel
- 241
Liao S S, Li R C, Li H. et al .
Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study
among Chinese children.
Vaccine.
1999;
17
2661-2666
MissingFormLabel
- 242
Liaw Y F.
Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
Semin Liver Dis.
2005;
25 (Suppl 1)
40-47
MissingFormLabel
- 243
Liaw Y F, Chen Y C, Sheen I S. et al .
Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis
B virus infection.
Gastroenterology.
2004;
126
1024-1029
MissingFormLabel
- 244
Liaw Y F, Chien R N, Yeh C T.
No benefit to continue lamivudine therapy after emergence of YMDD mutations.
Antivir Ther.
2004;
9
257-262
MissingFormLabel
- 245
Liaw Y F, Leung N W, Chang T T. et al .
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.
Asia Hepatitis Lamivudine Study Group.
Gastroenterology.
2000;
119
172-180
MissingFormLabel
- 246
Liaw Y F, Sung J J, Chow W C. et al .
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
N Engl J Med.
2004;
351
1521-1531
MissingFormLabel
- 247
Liaw Y F, Tsai S L, Sheen I S. et al .
Clinical and virological course of chronic hepatitis B virus infection with hepatitis
C and D virus markers.
Am J Gastroenterol.
1998;
93
354-359
MissingFormLabel
- 248
Lim L L, Wai C T, Lee Y M. et al .
Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.
Aliment Pharmacol Ther.
2002;
16
1939-1944
MissingFormLabel
- 249
Lim S G, Krastev Z, Ng T M. et al .
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone
in treatment of chronic hepatitis B.
Antimicrob Agents Chemother.
2006;
50
1642-1648
MissingFormLabel
- 250
Lin C C, Chen C L, Concejero A. et al .
Active immunization to prevent de novo hepatitis B virus infection in pediatric live
donor liver recipients.
Am J Transplant.
2007;
7
195-200
MissingFormLabel
- 251
Lin S M, Sheen I S, Chien R N. et al .
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis
B virus infection.
Hepatology.
1999;
29
971-975
MissingFormLabel
- 252
Lin S M, Yu M L, Lee C M. et al .
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis
and hepatocellular carcinoma.
J Hepatol.
2007;
46
45-52
MissingFormLabel
- 253
Lo C M, Liu C L, Lau G K. et al .
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant
using add-on adefovir dipivoxil plus lamivudine.
Liver Transpl.
2005;
11
807-813
MissingFormLabel
- 254
Locarnini S.
Molecular virology and the development of resistant mutants: implications for therapy.
Semin Liver Dis.
2005;
25 (Suppl 1)
9-19
MissingFormLabel
- 255
Locarnini S, Hatzakis A, Heathcote J. et al .
Management of antiviral resistance in patients with chronic hepatitis B.
Antivir Ther.
2004;
9
679-693
MissingFormLabel
- 256
Lok A S, Lai C L.
A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese
children.
Hepatology.
1988;
8
1130-1133
MissingFormLabel
- 257
Lok A S, Lai C L, Leung N. et al .
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
Gastroenterology.
2003;
125
1714-1722
MissingFormLabel
- 258
Lok A S, Liang R H, Chiu E K. et al .
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy.
Report of a prospective study.
Gastroenterology.
1991;
100
182-188
MissingFormLabel
- 259
Lok A S, McMahon B J.
AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines.
Rom J Gastroenterol.
2004;
13
150-154
MissingFormLabel
- 260
Looney R J, Hasan M S, Coffin D. et al .
Hepatitis B immunization of healthy elderly adults: relationship between naive CD4
+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant.
J Clin Immunol.
2001;
21
30-36
MissingFormLabel
- 261
Lucey M R, Graham D M, Martin P. et al .
Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation.
Gut.
1992;
33
1390-1396
MissingFormLabel
- 262
Madejon A, Cotonat T, Bartolome J. et al .
Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha
2a: utility of polymerase chain reaction in monitoring antiviral response.
Hepatology.
1994;
19
1331-1336
MissingFormLabel
- 263
Manesis E K, Hadziyannis S J.
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic
hepatitis B.
Gastroenterology.
2001;
121
101-109
MissingFormLabel
- 264
Manns M P, Wedemeyer H, Cornberg M.
Treating viral hepatitis C: efficacy, side effects, and complications.
Gut.
2006;
55
1350-1359
MissingFormLabel
- 265
Manzarbeitia C, Reich D J, Ortiz J A. et al .
Safe use of livers from donors with positive hepatitis B core antibody.
Liver Transpl.
2002;
8
556-561
MissingFormLabel
- 266
Marangi A L, Giordano R, Montanaro A. et al .
Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated
protocol of vaccination.
Am J Kidney Dis.
1994;
23
537-542
MissingFormLabel
- 267
Marcellin P, Boyer N, Colin J F. et al .
Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients
receiving zidovudine.
Gut.
1993;
34
S106
MissingFormLabel
- 268
Marcellin P, Chang T T, Lim S G. et al .
Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive
chronic hepatitis B (CHB) patients.
Hepatology.
2006;
44
548A
MissingFormLabel
- 269
Marcellin P, Chang T T, Lim S G. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis
B.
N Engl J Med.
2003;
348
808-816
MissingFormLabel
- 270
Marcellin P, Lau G K, Bonino F. et al .
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients
with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2004;
351
1206-1217
MissingFormLabel
- 271
Margreiter R, Kramar R, Huber C. et al .
Combined liver and kidney transplantation.
Lancet.
1984;
1
1077-1078
MissingFormLabel
- 272
Maria Elzbieta S L, Marek L D.
Histological outcome of chronic hepatitis B in children treated with interferon alpha.
World J Gastroenterol.
2005;
11
7179-7182
MissingFormLabel
- 273
Markovic S, Drozina G, Vovk M. et al .
Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma
and immunosuppressive therapy. A prospective study in 305 patients.
Hepatogastroenterology.
1999;
46
2925-2930
MissingFormLabel
- 274
Markowitz J S, Martin P, Conrad A J. et al .
Prophylaxis against hepatitis B recurrence following liver transplantation using combination
lamivudine and hepatitis B immune globulin.
Hepatology.
1998;
28
585-589
MissingFormLabel
- 275
Martinez E, Blanco J L, Arnaiz J A. et al .
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral
therapy.
AIDS.
2001;
15
1261-1268
MissingFormLabel
- 276
Marusawa H, Chiba T.
How can we prevent viral reactivation in liver transplantation from donors with latent
hepatitis B virus infection?.
J Gastroenterol.
2001;
36
212-213
MissingFormLabel
- 277
Marzano A, Salizzoni M, Debernardi-Venon W. et al .
Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic
patients treated with lamivudine and passive immunoprophylaxis.
J Hepatol.
2001;
34
903-910
MissingFormLabel
- 278
Mason W S, Taylor J M.
Liver transplantation: a model for the transmission of hepatitis delta virus.
Gastroenterology.
1991;
101
1741-1743
MissingFormLabel
- 279
Mast E E, Weinbaum C M, Fiore A E. et al .
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus
infection in the United States: recommendations of the Advisory Committee on Immunization
Practices (ACIP) Part II: immunization of adults.
MMWR Recomm Rep.
2006;
55
1-33
MissingFormLabel
- 280
Mathurin P, Mouquet C, Poynard T. et al .
Impact of hepatitis B and C virus on kidney transplantation outcome.
Hepatology.
1999;
29
257-263
MissingFormLabel
- 281
Mathurin P, Thibault V, Kadidja K. et al .
Replication status and histological features of patients with triple (B, C, D) and
dual (B, C) hepatic infections.
J Viral Hepat.
2000;
7
15-22
MissingFormLabel
- 282
McDonald J A, Harris S, Waters J A. et al .
Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic
viral antigen display.
J Hepatol.
1987;
4
337-342
MissingFormLabel
- 283
McMahon B J, Alward W L, Hall D B. et al .
Acute hepatitis B virus infection: relation of age to the clinical expression of disease
and subsequent development of the carrier state.
J Infect Dis.
1985;
151
599-603
MissingFormLabel
- 284 Mertens T, Haller O A, Klenk H D. Diagnostik und Therapie von Viruskrankheiten: Leitlinien der Gesellschaft für Virologie. München; Urban und Fischer-Verlag 2004
MissingFormLabel
- 285
Mettang T, Schenk U, Thomas S. et al .
Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with
end-stage renal failure. A preliminary study.
Nephron.
1996;
72
192-196
MissingFormLabel
- 286
Miro J M, Laguno M, Moreno A. et al .
Management of end stage liver disease (ESLD): what is the current role of orthotopic
liver transplantation (OLT)?.
J Hepatol.
2006;
44
S140-S145
MissingFormLabel
- 287
Mitsui T, Iwano K, Suzuki S. et al .
Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental
hepatitis B virus infection in hemodialysis staff members: comparison with immune
globulin without vaccine in historical controls.
Hepatology.
1989;
10
324-327
MissingFormLabel
- 288
Mitwalli A.
Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the
dose scheduling.
Nephron.
1996;
73
417-420
MissingFormLabel
- 289
Monteyne P, Andre F E.
Is there a causal link between hepatitis B vaccination and multiple sclerosis?.
Vaccine.
2000;
18
1994-2001
MissingFormLabel
- 290
Mutchnick M G, Lindsay K L, Schiff E R. et al .
Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre,
randomized, double-blind and placebo-controlled study.
J Viral Hepat.
1999;
6
397-403
MissingFormLabel
- 291
Myers R P, Tainturier M H, Ratziu V. et al .
Prediction of liver histological lesions with biochemical markers in patients with
chronic hepatitis B.
J Hepatol.
2003;
39
222-230
MissingFormLabel
- 292
Nagamatsu H, Itano S, Nagaoka S. et al .
Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe
antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial
infusion chemotherapy.
Am J Gastroenterol.
2004;
99
2369-2375
MissingFormLabel
- 293
Nagamatsu H, Kumashiro R, Itano S. et al .
Investigation of associating factors in exacerbation of liver damage after chemotherapy
in patients with HBV-related HCC.
Hepatol Res.
2003;
26
293-301
MissingFormLabel
- 294
Nakamura Y, Motokura T, Fujita A. et al .
Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic
malignancies. Survey in Japan, 1987 - 1991.
Cancer.
1996;
78
2210-2215
MissingFormLabel
- 295
Neff G W, Bonham A, Tzakis A G. et al .
Orthotopic liver transplantation in patients with human immunodeficiency virus and
end-stage liver disease.
Liver Transpl.
2003;
9
239-247
MissingFormLabel
- 296
Neff G W, Nery J, Lau D T. et al .
Tenofovir therapy for lamivudine resistance following liver transplantation.
Ann Pharmacother.
2004;
38
1999-2004
MissingFormLabel
- 297
Neumann U P, Lang M, Moldenhauer A. et al .
Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney
transplantation.
Transplantation.
2001;
71
1163-1168
MissingFormLabel
- 298
Ni Y H, Huang F C, Wu T C. et al .
Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection
patients.
Pediatr Int.
2005;
47
372-377
MissingFormLabel
- 299
Niederau C, Heintges T, Lange S. et al .
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic
hepatitis B.
N Engl J Med.
1996;
334
1422-1427
MissingFormLabel
- 300
Niro G A, Ciancio A, Gaeta G B. et al .
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic
hepatitis delta.
Hepatology.
2006;
44
713-720
MissingFormLabel
- 301
Ohtsu T, Sai T, Oka M. et al .
Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid
in hepatitis B virus carriers with hematologic malignancies.
Jpn J Clin Oncol.
1991;
21
360-365
MissingFormLabel
- 302
Olausson M, Mjornstedt L, Norden G. et al .
Successful combined partial auxiliary liver and kidney transplantation in highly sensitized
cross-match positive recipients.
Am J Transplant.
2007;
7
130-136
MissingFormLabel
- 303
Ollenschlager G, Kopp I, Lelgemann M. et al .
The German program for disease management guidelines. Background, methods, and development
process.
Med Klin (Munich).
2006;
101
840-845
MissingFormLabel
- 304
Onozawa M, Hashino S, Izumiyama K. et al .
Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse
seroconversion after allogeneic hematopoietic stem cell transplantation in patients
with previous hepatitis B virus infection.
Transplantation.
2005;
79
616-619
MissingFormLabel
- 305
Ozgenc F, Arikan C, Sertoz R Y. et al .
Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Antivir Ther.
2004;
9
729-732
MissingFormLabel
- 306
Ozguroglu M, Bilici A, Turna H. et al .
Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin’s
lymphoma.
Med Oncol.
2004;
21
67-72
MissingFormLabel
- 307
Palmer D R, Perry K R, Mortimer P P. et al .
Variation in the sensitivity of HBsAg screening kits.
Transfus Med.
1996;
6
311-317
MissingFormLabel
- 308
Papatheodoridis G V, Dimou E, Laras A. et al .
Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore
mutant HBV liver disease.
Hepatology.
2002;
36
219-226
MissingFormLabel
- 309
Papatheodoridis G V, Manesis E, Hadziyannis S J.
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative
chronic hepatitis B.
J Hepatol.
2001;
34
306-313
MissingFormLabel
- 310
Park J W, Park K W, Cho S H. et al .
Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization
therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective
study.
Am J Gastroenterol.
2005;
100
2194-2200
MissingFormLabel
- 311
Pastore G, Santantonio T, Monno L. et al .
Permanent inhibition of viral replication induced by low dosage of human leukocyte
interferon in patients with chronic hepatitis B.
Hepatogastroenterology.
1988;
35
57-61
MissingFormLabel
- 312
Perrillo R, Hann H W, Mutimer D. et al .
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant
hepatitis B virus.
Gastroenterology.
2004;
126
81-90
MissingFormLabel
- 313
Perrillo R P, Lai C L, Liaw Y F. et al .
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Hepatology.
2002;
36
186-194
MissingFormLabel
- 314
Perrillo R P, Wright T, Rakela J. et al .
A multicenter United States-Canadian trial to assess lamivudine monotherapy before
and after liver transplantation for chronic hepatitis B.
Hepatology.
2001;
33
424-432
MissingFormLabel
- 315
Persico M, De Marino F, Russo G D. et al .
Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected
patients treated for non-Hodgkin lymphoma.
Blood.
2002;
99
724-725
MissingFormLabel
- 316
Perz J F, Armstrong G L, Farrington L A. et al .
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis
and primary liver cancer worldwide.
J Hepatol.
2006;
45
529-538
MissingFormLabel
- 317
Peters M G, Andersen J, Lynch P. et al .
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus
and HIV infection: ACTG A5127.
Hepatology.
2006;
44
1110-1116
MissingFormLabel
- 318
Peters M G, Hann H H, Martin P. et al .
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant
chronic hepatitis B.
Gastroenterology.
2004;
126
91-101
MissingFormLabel
- 319
Pineda J A, Romero-Gomez M, Diaz-Garcia F. et al .
HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated
cirrhosis.
Hepatology.
2005;
41
779-789
MissingFormLabel
- 320
Pirson Y, Alexandre G P, Ypersele C.
Long-term effect of HBs antigenemia on patient survival after renal transplantation.
N Engl J Med.
1977;
296
194-196
MissingFormLabel
- 321
Poge U, Gerhardt T, Palmedo H. et al .
MDRD equations for estimation of GFR in renal transplant recipients.
Am J Transplant.
2005;
5
1306-1311
MissingFormLabel
- 322
Pol S, Wesenfelder L, Dubois F. et al .
Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection
in chronic HBsAg carriers.
J Viral Hepat.
1994;
1
131-137
MissingFormLabel
- 323
Pollicino T, Squadrito G, Cerenzia G. et al .
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV
infection.
Gastroenterology.
2004;
126
102-110
MissingFormLabel
- 324
Pontisso P, Ruvoletto M G, Fattovich G. et al .
Clinical and virological profiles in patients with multiple hepatitis virus infections.
Gastroenterology.
1993;
105
1529-1533
MissingFormLabel
- 325
Poynard T, Zoulim F, Ratziu V. et al .
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during
lamivudine therapy in patients with chronic hepatitis B infection.
Am J Gastroenterol.
2005;
100
1970-1980
MissingFormLabel
- 326
Prakoso E, Strasser S I, Koorey D J. et al .
Long-term lamivudine monotherapy prevents development of hepatitis B virus infection
in hepatitis B surface-antigen negative liver transplant recipients from hepatitis
B core-antibody-positive donors.
Clin Transplant.
2006;
20
369-373
MissingFormLabel
- 327
Pramoolsinsap C, Poovorawan Y, Hirsch P. et al .
Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related
to HBV or HCV.
Ann Trop Med Parasitol.
1999;
93
745-751
MissingFormLabel
- 328
Prieto M, Gomez M D, Berenguer M. et al .
De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive
donors in an area with high prevalence of anti-HBc positivity in the donor population.
Liver Transpl.
2001;
7
51-58
MissingFormLabel
- 329
Propst T, Propst A, Lhotta K. et al .
Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior
in antibody response to intramuscular or subcutaneous vaccination.
Am J Kidney Dis.
1998;
32
1041-1045
MissingFormLabel
- 330
Protzer-Knolle U, Naumann U, Bartenschlager R. et al .
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected
by high-dose hepatitis B immune globulin after liver transplantation.
Hepatology.
1998;
27
254-263
MissingFormLabel
- 331
Puoti M, Airoldi M, Bruno R. et al .
Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.
AIDS Rev.
2002;
4
27-35
MissingFormLabel
- 332
Puoti M, Cozzi-Lepri A, Arici C. et al .
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive
individuals: results from an inter-cohort analysis.
Antivir Ther.
2006;
11
567-574
MissingFormLabel
- 333
Puoti M, Torti C, Bruno R. et al .
Natural history of chronic hepatitis B in co-infected patients.
J Hepatol.
2006;
44
S65-S70
MissingFormLabel
- 334
Ragni M V, Belle S H, Im K. et al .
Survival of human immunodeficiency virus-infected liver transplant recipients.
J Infect Dis.
2003;
188
1412-1420
MissingFormLabel
- 335
Ragni M V, Eghtesad B, Schlesinger K W. et al .
Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with
end-stage liver disease.
Liver Transpl.
2005;
11
1425-1430
MissingFormLabel
- 336
Rahman F, Dahmen A, Herzog-Hauff S. et al .
Cellular and humoral immune responses induced by intradermal or intramuscular vaccination
with the major hepatitis B surface antigen.
Hepatology.
2000;
31
521-527
MissingFormLabel
- 337
Raimondo G, Pollicino T, Cacciola I. et al .
Occult hepatitis B virus infection.
J Hepatol.
2007;
46
160-170
MissingFormLabel
- 338
Ranger-Rogez S, Denis F.
Hepatitis B mother-to-child transmission.
Expert Rev Anti Infect Ther.
2004;
2
133-145
MissingFormLabel
- 339
Rehermann B, Nascimbeni M.
Immunology of hepatitis B virus and hepatitis C virus infection.
Nat Rev Immunol.
2005;
5
215-229
MissingFormLabel
- 340
Rendi-Wagner P, Wiedermann G, Stemberger H. et al .
New vaccination strategies for low- and non-responders to hepatitis B vaccine.
Wien Klin Wochenschr.
2002;
114
175-180
MissingFormLabel
- 341
Resti M, Azzari C, Mannelli F. et al .
Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections
indicated?.
Vaccine.
1997;
15
1338-1340
MissingFormLabel
- 342
Rizzetto M.
Hepatitis D: virology, clinical and epidemiological aspects.
Acta Gastroenterol Belg.
2000;
63
221-224
MissingFormLabel
- 343
Rizzetto M.
Hepatitis delta: the virus and the disease.
J Hepatol.
1990;
11 (Suppl 1)
S145-S148
MissingFormLabel
- 344
Rizzetto M, Macagno S, Chiaberge E. et al .
Liver transplantation in hepatitis delta virus disease.
Lancet.
1987;
2
469-471
MissingFormLabel
- 345
Rizzetto M, Verme G, Recchia S. et al .
Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression
of the delta antigen. An active and progressive disease unresponsive to immunosuppressive
treatment.
Ann Intern Med.
1983;
98
437-441
MissingFormLabel
- 346
Robert Koch-Institut .
Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C
und D im Jahr 2005.
Epidem Bull.
2006;
46
MissingFormLabel
- 347
Robert Koch-Institut .
Mitteilungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise
für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen.
Epidem Bull.
2004;
6
33-52
MissingFormLabel
- 348
Robert Koch-Institut .
Virushepatitis B, C und D im Jahre 2004.
Epidem Bull.
2005;
46
421-236
MissingFormLabel
- 349
Robert Koch-Institut .
Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand Juli
2006.
Epidem Bull.
2006;
30
235-254
MissingFormLabel
- 350
Roche B, Samuel D, Gigou M. et al .
De novo and apparent de novo hepatitis B virus infection after liver transplantation.
J Hepatol.
1997;
26
517-526
MissingFormLabel
- 351
Rockstroh J K.
Influence of viral hepatitis on HIV infection.
J Hepatol.
2006;
44
S25-S27
MissingFormLabel
- 352
Rodella A, Galli C, Terlenghi L. et al .
Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic
hepatitis B.
J Clin Virol.
2006;
37
206-212
MissingFormLabel
- 353
Romand F, Michallet M, Pichoud C. et al .
Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient
previously cured of hepatitis B.
Gastroenterol Clin Biol.
1999;
23
770-774
MissingFormLabel
- 354
Roque-Afonso A M, Feray C, Samuel D. et al .
Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients
of liver grafts from anti-HBC positive donors.
Gut.
2002;
50
95-99
MissingFormLabel
- 355
Rosenau J, Bahr M J, Tillmann H L. et al .
Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B
reinfection after liver transplantation possible role of mutations in the YMDD motif
prior to transplantation as a risk factor for reinfection.
J Hepatol.
2001;
34
895-902
MissingFormLabel
- 356
Rosenau J, Hooman N, Rifai K. et al .
Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation
for hepatitis B-related disease: failure of humoral and cellular immune response.
Transpl Int.
2006;
19
828-833
MissingFormLabel
- 357
Rosina F, Pintus C, Meschievitz C. et al .
A randomized controlled trial of a 12-month course of recombinant human interferon-alpha
in chronic delta (type D) hepatitis: a multicenter Italian study.
Hepatology.
1991;
13
1052-1056
MissingFormLabel
- 358
Rosina F, Rizzetto M.
Treatment of chronic type D (delta) hepatitis with alpha interferon.
Semin Liver Dis.
1989;
9
264-266
MissingFormLabel
- 359
Rosman A S, Basu P, Galvin K. et al .
Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients:
a randomized clinical trial.
Am J Med.
1997;
103
217-222
MissingFormLabel
- 360
Rossi G, Pelizzari A, Motta M. et al .
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAG
carriers with lymphoid malignancies treated with chemotherapy.
Br J Haematol.
2001;
115
58-62
MissingFormLabel
- 361
Ruiz R, Kunitake H, Wilkinson A H. et al .
Long-term analysis of combined liver and kidney transplantation at a single center.
Arch Surg.
2006;
141
735-741
MissingFormLabel
- 362
Ryu S H, Chung Y H, Choi M H. et al .
Long-term additional lamivudine therapy enhances durability of lamivudine-induced
HBeAg loss: a prospective study.
J Hepatol.
2003;
39
614-619
MissingFormLabel
- 363
Sadovnick A D, Scheifele D W.
School-based hepatitis B vaccination programme and adolescent multiple sclerosis.
Lancet.
2000;
355
549-550
MissingFormLabel
- 364
Sagnelli E, Coppola N, Scolastico C. et al .
Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B,
C, and delta viruses in patients with chronic hepatitis.
Hepatology.
2000;
32
1106-1110
MissingFormLabel
- 365
Sagnelli E, Pasquale G, Coppola N. et al .
Influence of chronic coinfection with hepatitis B and C virus on liver histology.
Infection.
2004;
32
144-148
MissingFormLabel
- 366
Sakallioglu O, Gok F, Kalman S. et al .
Hepatitis B complicated focal segmental glomerulosclerosis.
J Nephrol.
2005;
18
433-435
MissingFormLabel
- 367
Saltik-Temizel I N, Kocak N, Demir H.
Interferon-alpha and lamivudine combination therapy of children with chronic hepatitis
b infection who were interferon-alpha nonresponders.
Pediatr Infect Dis J.
2004;
23
466-468
MissingFormLabel
- 368
Saltik-Temizel I N, Kocak N, Demir H.
Lamivudine and high-dose interferon-alpha combination therapy for naive children with
chronic hepatitis B infection.
J Clin Gastroenterol.
2005;
39
68-70
MissingFormLabel
- 369
Samuel D, Muller R, Alexander G. et al .
Liver transplantation in European patients with the hepatitis B surface antigen.
N Engl J Med.
1993;
329
1842-1847
MissingFormLabel
- 370
Samuel D, Zignego A L, Reynes M. et al .
Long-term clinical and virological outcome after liver transplantation for cirrhosis
caused by chronic delta hepatitis.
Hepatology.
1995;
21
333-339
MissingFormLabel
- 371
Sanchez-Fueyo A, Rimola A, Grande L. et al .
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination:
A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
Hepatology.
2000;
31
496-501
MissingFormLabel
- 372
Saracco G, Rosina F, Brunetto M R. et al .
Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta
virus infection.
J Hepatol.
1987;
5
274-281
MissingFormLabel
- 373
Sarrecchia C, Cappelli A, Aiello P.
HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a
subject negative for HBsAg and positive for HBsAb and HBcAb.
J Infect Chemother.
2005;
11
189-191
MissingFormLabel
- 374
Schattner A.
Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune
manifestations after viral vaccines.
Vaccine.
2005;
23
3876-3886
MissingFormLabel
- 375
Scheiblauer H, Soboll H, Nick S.
Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical
sensitivity, and hepatitis B virus mutant detection.
J Med Virol.
2006;
78 (Suppl 1)
S66-S70
MissingFormLabel
- 376
Schiff E R, Lai C L, Hadziyannis S. et al .
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver
transplantation patients.
Hepatology.
2003;
38
1419-1427
MissingFormLabel
- 377
Schildgen O, Sirma H, Funk A. et al .
Variant of hepatitis B virus with primary resistance to adefovir.
N Engl J Med.
2006;
354
1807-1812
MissingFormLabel
- 378
Schirmacher P, Fleig W E, Tannapfel A. et al .
Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference
of the German Society of Pathology, of the German Society for Digestive and Metabolic
Diseases and of Compensated Hepatitis (HepNet).
Pathologe.
2004;
25
337-348
MissingFormLabel
- 379
Schmilovitz-Weiss H, Ben Ari Z, Sikuler E. et al .
Lamivudine treatment for acute severe hepatitis B: a pilot study.
Liver Int.
2004;
24
547-551
MissingFormLabel
- 380
Schmutz G, Nelson M, Lutz T. et al .
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure
for therapy of hepatitis B in HIV-coinfection.
AIDS.
2006;
20
1951-1954
MissingFormLabel
- 381
Seaworth B, Drucker J, Starling J. et al .
Hepatitis B vaccines in patients with chronic renal failure before dialysis.
J Infect Dis.
1988;
157
332-337
MissingFormLabel
- 382
Segovia R, Sanchez-Fueyo A, Rimola A. et al .
Evidence of serious graft damage induced by de novo hepatitis B virus infection after
liver transplantation.
Liver Transpl.
2001;
7
106-112
MissingFormLabel
- 383
Seth P, Alrajhi A A, Kagevi I. et al .
Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants
with chronic graft-versus-host disease.
Bone Marrow Transplant.
2002;
30
189-194
MissingFormLabel
- 384
Shattock A G, Morris M C.
Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen
and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies.
J Clin Microbiol.
1991;
29
1873-1876
MissingFormLabel
- 385
Sheldon J, Camino N, Rodes B. et al .
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated
with tenofovir.
Antivir Ther.
2005;
10
727-734
MissingFormLabel
- 386
Sheldon J A, Corral A, Rodes B. et al .
Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic
hepatitis B treated with adefovir.
AIDS.
2005;
19
2036-2038
MissingFormLabel
- 387
Sheng W H, Hung C C, Kao J H. et al .
Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis
B virus and HIV coinfection in the era of highly active antiretroviral therapy: a
matched cohort study.
Clin Infect Dis.
2007;
44
988-995
MissingFormLabel
- 388
Sherman M, Peltekian K M, Lee C.
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence
and prevalence of hepatocellular carcinoma in a North American urban population.
Hepatology.
1995;
22
432-438
MissingFormLabel
- 389
Sherman M, Yurdaydin C, Sollano J. et al .
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis
B.
Gastroenterology.
2006;
130
2039-2049
MissingFormLabel
- 390
Shibolet O, Ilan Y, Gillis S. et al .
Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation
in hepatitis B surface antigen carriers.
Blood.
2002;
100
391-396
MissingFormLabel
- 391
Silvestri F, Sperotto A, Ermacora A. et al .
Lamivudine for the prevention of hepatitis B virus reactivation during autologous
stem cell transplantation. A case report.
Haematologica.
2000;
85
327-329
MissingFormLabel
- 392
Smedile A, Farci P, Verme G. et al .
Influence of delta infection on severity of hepatitis B.
Lancet.
1982;
2
945-947
MissingFormLabel
- 393
Sokal E.
Drug treatment of pediatric chronic hepatitis B.
Paediatr Drugs.
2002;
4
361-369
MissingFormLabel
- 394
Sokal E M, Kelly D A, Mizerski J. et al .
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.
Hepatology.
2006;
43
225-232
MissingFormLabel
- 395
Soriano V, Barreiro P, Nunez M.
Management of chronic hepatitis B and C in HIV-coinfected patients.
J Antimicrob Chemother.
2006;
57
815-818
MissingFormLabel
- 396
Soriano V, Puoti M, Bonacini M. et al .
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from
an HIV-HBV International Panel.
AIDS.
2005;
19
221-240
MissingFormLabel
- 397
Spengler U, Lichterfeld M, Rockstroh J K.
Antiretroviral drug toxicity - a challenge for the hepatologist?.
J Hepatol.
2002;
36
283-294
MissingFormLabel
- 398
Sponseller C A, Bacon B R, Di Bisceglie A M.
Clinical improvement in patients with decompensated liver disease caused by hepatitis
B after treatment with lamivudine.
Liver Transpl.
2000;
6
715-720
MissingFormLabel
- 399
Starkel P, Stoffel M, Lerut J. et al .
Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in
fulminant and selected chronic HBV-infected liver graft recipients.
Liver Transpl.
2005;
11
1228-1234
MissingFormLabel
- 400
Steinmuller T, Seehofer D, Rayes N. et al .
Increasing applicability of liver transplantation for patients with hepatitis B-related
liver disease.
Hepatology.
2002;
35
1528-1535
MissingFormLabel
- 401
Stevens C E, Alter H J, Taylor P E. et al .
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.
N Engl J Med.
1984;
311
496-501
MissingFormLabel
- 402
Su C W, Huang Y H, Huo T I. et al .
Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of
chronic hepatitis D patients.
Gastroenterology.
2006;
130
1625-1635
MissingFormLabel
- 403
Su G G, Pan K H, Zhao N F. et al .
Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy.
World J Gastroenterol.
2004;
10
910-912
MissingFormLabel
- 404
Sung J JY, Lai J Y, Zeuzem S. et al .
A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine
plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis
B (CHB): Week 52 analysis.
Journal of Hepatology.
2003;
38
25-26
MissingFormLabel
- 405
Tabor E.
Infections by hepatitis B surface antigen gene mutants in Europe and North America.
J Med Virol.
2006;
78 (Suppl 1)
S43-S47
MissingFormLabel
- 406
Tang J R, Cova L, Lamelin J P. et al .
Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization
and polymerase chain reaction.
J Hepatol.
1994;
21
953-960
MissingFormLabel
- 407
Tassopoulos N C, Papaevangelou G J, Sjogren M H. et al .
Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.
Gastroenterology.
1987;
92
1844-1850
MissingFormLabel
- 408
Tenderich G, Zittermann A, Prohaska W. et al .
Frequent detection of hepatitis B core antibodies in heart transplant recipients without
preceding hepatitis B infection.
Transplant Proc.
2005;
37
4522-4524
MissingFormLabel
- 409
Tenney D, Baldick C J, Rose R E. et al .
Only a subset of HBV substitutions at entecavir resistance residues lead to phenotypic
resistance and virologic rebound.
Hepatology.
2006;
44
253A-254A
MissingFormLabel
- 410
ter Borg F, Smorenburg S, Man R A. et al .
Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related
reactivation of hepatitis B associated with lamivudine therapy.
Dig Dis Sci.
1998;
43
2267-2270
MissingFormLabel
- 411
Terrault de N, Roche B, Samuel D.
Management of the hepatitis B virus in the liver transplantation setting: a European
and an American perspective.
Liver Transpl.
2005;
11
716-732
MissingFormLabel
- 412
Thierfelder W, Hellenbrand W, Meisel H. et al .
Prevalence of markers for hepatitis A, B and C in the German population. Results of
the German National Health Interview and Examination Survey 1998.
Eur J Epidemiol.
2001;
17
429-435
MissingFormLabel
- 413
Thio C L.
Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural
history, and treatment.
Semin Liver Dis.
2003;
23
125-136
MissingFormLabel
- 414
Thio C L, Seaberg E C, Skolasky R Jr. et al .
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort
Study (MACS).
Lancet.
2002;
360
1921-1926
MissingFormLabel
- 415 Thomas H C, Lemon S, Zuckerman A J. Viral Hepatitis. Thomas HC, Lemon S, Zuckerman AJ Blackwell Publishing 2005
MissingFormLabel
- 416
Tillmann H L, Hadem J, Leifeld L. et al .
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis
B, a multicenter experience.
J Viral Hepat.
2006;
13
256-263
MissingFormLabel
- 417
Tseng P L, Lu S N, Tung H D. et al .
Determinants of early mortality and benefits of lamivudine therapy in patients with
hepatitis B virus-related decompensated liver cirrhosis.
J Viral Hepat.
2005;
12
386-392
MissingFormLabel
- 418
Tsutsumi Y, Tanaka J, Kawamura T. et al .
Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation
due to rituximab therapy in a patient with non-Hodgkin’s lymphoma.
Ann Hematol.
2004;
83
58-60
MissingFormLabel
- 419
Uemoto S, Inomata Y, Sannomiya A. et al .
Posttransplant hepatitis B infection in liver transplantation with hepatitis B core
antibody-positive donors.
Transplant Proc.
1998;
30
134-135
MissingFormLabel
- 420
Bommel van F, Wunsche T, Mauss S. et al .
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis
B virus infection.
Hepatology.
2004;
40
1421-1425
MissingFormLabel
- 421
Bommel van F, Zollner B, Sarrazin C. et al .
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection
and high HBV DNA level during adefovir therapy.
Hepatology.
2006;
44
318-325
MissingFormLabel
- 422
Van Damme P, Kane M, Meheus A.
Integration of hepatitis B vaccination into national immunisation programmes. Viral
Hepatitis Prevention Board.
BMJ.
1997;
314
1033-1036
MissingFormLabel
- 423
Nunen A B, Hansen B E, Suh D J. et al .
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis
B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine
aminotransferase.
Gut.
2003;
52
420-424
MissingFormLabel
- 424
Zonneveld van M, Nunen van A B, Niesters H G. et al .
Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis
B virus infection.
J Viral Hepat.
2003;
10
294-297
MissingFormLabel
- 425
Vassiliadis van T, Garipidou V, Tziomalos K. et al .
Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers
with hematologic malignancies treated with chemotherapy - a prospective case series.
Am J Hematol.
2005;
80
197-203
MissingFormLabel
- 426
Verme G, Brunetto M R, Oliveri F. et al .
Role of hepatitis delta virus infection in hepatocellular carcinoma.
Dig Dis Sci.
1991;
36
1134-1136
MissingFormLabel
- 427
Villa E, Grottola A, Buttafoco P. et al .
High doses of alpha-interferon are required in chronic hepatitis due to coinfection
with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized
trial.
Am J Gastroenterol.
2001;
96
2973-2977
MissingFormLabel
- 428
Villeneuve E, Vincelette J, Villeneuve J P.
Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver
transplantation.
Can J Gastroenterol.
2000;
14 (Suppl B)
59B-62B
MissingFormLabel
- 429
Villeneuve J P, Condreay L D, Willems B. et al .
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis
B.
Hepatology.
2000;
31
207-210
MissingFormLabel
- 430
Villeneuve J P, Durantel D, Durantel S. et al .
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation
patient.
J Hepatol.
2003;
39
1085-1089
MissingFormLabel
- 431
Vo Thi D H, Bourgois A, Bontems P. et al .
Chronic hepatitis B infection: long term comparison of children receiving interferon
alpha and untreated controls.
J Pediatr Gastroenterol Nutr.
2005;
40
141-145
MissingFormLabel
- 432
Wai C T, Chu C J, Hussain M. et al .
HBV genotype B is associated with better response to interferon therapy in HBeAg(+)
chronic hepatitis than genotype C.
Hepatology.
2002;
36
1425-1430
MissingFormLabel
- 433
Wainwright R B, Bulkow L R, Parkinson A J. et al .
Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results
of a 10-year study.
J Infect Dis.
1997;
175
674-677
MissingFormLabel
- 434
Waked I, Amin M, Abd E F. et al .
Experience with interferon in chronic hepatitis B in Egypt.
J Chemother.
1990;
2
310-318
MissingFormLabel
- 435
Walker U A, Bauerle J, Laguno M. et al .
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine,
stavudine, or zalcitabine.
Hepatology.
2004;
39
311-317
MissingFormLabel
- 436
Walter J, Radun D, Claus H. et al .
Hepatitis B and C risk factors in Germany - results of the national surveillance.
Gesundheitswesen.
2005;
67
441-447
MissingFormLabel
- 437
Wands J R, Chura C M, Roll F J. et al .
Serial studies of hepatitis-associated antigen and antibody in patients receiving
antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders.
Gastroenterology.
1975;
68
105-112
MissingFormLabel
- 438
Wartelle-Bladou C, Lafon J, Trepo C. et al .
Successful combination therapy of polyarteritis nodosa associated with a pre-core
promoter mutant hepatitis B virus infection.
J Hepatol.
2001;
34
774-779
MissingFormLabel
- 439
Watson B, West D J, Chilkatowsky A. et al .
Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis
B vaccine.
Vaccine.
2001;
19
3164-3168
MissingFormLabel
- 440
Weber B.
Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact.
J Clin Virol.
2005;
32
102-112
MissingFormLabel
- 441
Wedemeyer H, Cornberg M, Tegtmeyer B. et al .
Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with
hepatitis C virus replication.
Clin Microbiol Infect.
2004;
10
70-72
MissingFormLabel
- 442
Weltman M D, Brotodihardjo A, Crewe E B. et al .
Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic
liver disease and responds poorly to interferon-alpha treatment.
J Viral Hepat.
1995;
2
39-45
MissingFormLabel
- 443
Wen Y K, Chen M L.
Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis
in a cirrhotic patient after lamivudine therapy.
Clin Nephrol.
2006;
65
211-215
MissingFormLabel
- 444
West D J, Calandra G B.
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for
policy on booster vaccination.
Vaccine.
1996;
14
1019-1027
MissingFormLabel
- 445
Westhoff T H, Jochimsen F, Schmittel A. et al .
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.
Blood.
2003;
102
1930
MissingFormLabel
- 446
Westland C, Delaney W, Yang H. et al .
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies
of adefovir dipivoxil1.
Gastroenterology.
2003;
125
107-116
MissingFormLabel
- 447
Westland C E, Yang H, Delaney W E. et al .
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil
for chronic hepatitis B.
Hepatology.
2003;
38
96-103
MissingFormLabel
- 448
Whittle H, Jaffar S, Wansbrough M. et al .
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination
in Gambian children.
BMJ.
2002;
325
569
MissingFormLabel
- 449
Wiegand J, Hasenclever D, Tillman H L.
Should treatment of hepatitis B depend on HBV genotypes? - A hypothesis generated
from an explorative analysis of published evidence.
Hepatology.
2006;
44
564A-565A
MissingFormLabel
- 450
Williams R.
Global challenges in liver disease.
Hepatology.
2006;
44
521-526
MissingFormLabel
- 451
Wintermeyer P, Gerner P, Gehring S. et al .
Prevalence of hepatitis B virus precore stop codon mutations in chronically infected
children.
World J Gastroenterol.
2006;
12
2235-2238
MissingFormLabel
- 452
Wismans P, Hattum van J, Stelling T. et al .
Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination.
Hepatogastroenterology.
1988;
35
78-79
MissingFormLabel
- 453
Wit F W, Weverling G J, Weel J. et al .
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral
combination therapy.
J Infect Dis.
2002;
186
23-31
MissingFormLabel
- 454
Wolters L M, Nunen A B, Honkoop van P. et al .
Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients
co-infected with the hepatitis D virus.
J Viral Hepat.
2000;
7
428-434
MissingFormLabel
- 455
Wong D K, Cheung A M, O’Rourke K. et al .
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive
chronic hepatitis B. A meta-analysis.
Ann Intern Med.
1993;
119
312-323
MissingFormLabel
- 456
Wong D K, Yim C, Naylor C D. et al .
Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly
homosexual male population.
Gastroenterology.
1995;
108
165-171
MissingFormLabel
- 457
Wong V W, Chan H L, Wong M L. et al .
Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant
mutants.
Aliment Pharmacol Ther.
2004;
19
323-329
MissingFormLabel
- 458
World Health Organisation .
Hepatitis Delta. Electronic Citation.
2001;
, http://www.who.int/csr/
MissingFormLabel
- 459
World Health Organisation.
Hepatitis B. Electronic Citation.
2002;
, http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf
MissingFormLabel
- 460
Wursthorn K, Buggisch P, Lutgehetmann M. et al .
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination
therapy followed by relapse of HBV.
Antivir Ther.
2006;
11
647-652
MissingFormLabel
- 461
Wursthorn K, Lutgehetmann M, Dandri M. et al .
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction
in patients with chronic hepatitis B.
Hepatology.
2006;
44
675-684
MissingFormLabel
- 462
Yang B, Zhang B, Xu Y. et al .
Prospective study of early detection for primary liver cancer.
J Cancer Res Clin Oncol.
1997;
123
357-360
MissingFormLabel
- 463
Yang H I, Lu S N, Liaw Y F. et al .
Hepatitis B e antigen and the risk of hepatocellular carcinoma.
N Engl J Med.
2002;
347
168-174
MissingFormLabel
- 464
Yao F Y, Terrault N A, Freise C. et al .
Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis
and actively replicating hepatitis B infection awaiting liver transplantation: a comparative
study using a matched, untreated cohort.
Hepatology.
2001;
34
411-416
MissingFormLabel
- 465
Yeo W, Chan P K, Ho W M. et al .
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen
seropositive cancer patients undergoing cytotoxic chemotherapy.
J Clin Oncol.
2004;
22
927-934
MissingFormLabel
- 466
Yeo W, Chan P K, Zhong S. et al .
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic
chemotherapy: a prospective study of 626 patients with identification of risk factors.
J Med Virol.
2000;
62
299-307
MissingFormLabel
- 467
Yeo W, Johnson P J.
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer
therapy.
Hepatology.
2006;
43
209-220
MissingFormLabel
- 468
Yeo W, Steinberg J L, Tam J S. et al .
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
J Med Virol.
1999;
59
263-269
MissingFormLabel
- 469
Yeo W, Zee B, Zhong S. et al .
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation
in cancer patients undergoing cytotoxic chemotherapy.
Br J Cancer.
2004;
90
1306-1311
MissingFormLabel
- 470
Yu A S, Vierling J M, Colquhoun S D. et al .
Transmission of hepatitis B infection from hepatitis B core antibody-positive liver
allografts is prevented by lamivudine therapy.
Liver Transpl.
2001;
7
513-517
MissingFormLabel
- 471
Yuen M F, Sablon E, Hui C K. et al .
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged
lamivudine therapy.
Hepatology.
2001;
34
785-791
MissingFormLabel
- 472
Yurdaydin C, Bozkaya H, Gurel S. et al .
Famciclovir treatment of chronic delta hepatitis.
J Hepatol.
2002;
37
266-271
MissingFormLabel
- 473
Yurdaydin C, Wedemeyer H, Zachou K. et al .
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a
plus adefovir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adefovir
dipivoxil for the treatment of chronic delta hepatitis.
Hepatology.
2006;
44
230A
MissingFormLabel
- 474
Zanetti A R, Mariano A, Romano L. et al .
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian
multicentre study.
Lancet.
2005;
366
1379-1384
MissingFormLabel
- 475
Zarski J P, Bohn B, Bastie A. et al .
Characteristics of patients with dual infection by hepatitis B and C viruses.
J Hepatol.
1998;
28
27-33
MissingFormLabel
- 476
Zavaglia C, Severini R, Tinelli C. et al .
A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe,
HBV-DNA-positive chronic hepatitis B.
Dig Dis Sci.
2000;
45
690-696
MissingFormLabel
- 477
Zignego A L, Fontana R, Puliti S. et al .
Impaired response to alpha interferon in patients with an inapparent hepatitis B and
hepatitis C virus coinfection.
Arch Virol.
1997;
142
535-544
MissingFormLabel
- 478
Zollner B, Schafer P, Feucht H H. et al .
Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant
variants during lamivudine therapy.
J Med Virol.
2001;
65
659-663
MissingFormLabel
- 479
Zoulim F.
New insight on hepatitis B virus persistence from the study of intrahepatic viral
cccDNA.
J Hepatol.
2005;
42
302-308
MissingFormLabel
- 480
Zuccotti G V, Cucchi C, Gracchi V. et al .
A 1-year trial of lamivudine for chronic hepatitis B in children.
J Int Med Res.
2002;
30
200-202
MissingFormLabel
- 481
Zylberberg H, Jiang J, Pialoux G. et al .
Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected
patients.
Gastroenterol Clin Biol.
1996;
20
968-971
MissingFormLabel
Prof. Dr. Michael P. Manns
Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule
Hannover
Carl-Neuberg-Straße 1
30625 Hannover
Email: manns.michael@mh-hannover.de